University of Ioannina
Σχεδιασμός, σύνθεση και βιολογικός έλεγχος νέων αναλόγων του φαρμακευτικού σκευάσματος Lenvatinib ως εν δυνάμει αναστολέων του υποδοχέα του αγγειακού ενδοθηλιακού αυξητικού παράγοντα 2 (VEGFR2) και βελτιστοποίηση της συνθετικής του πορείας
Abstract
dc:descriptionThe selective inhibition of protein kinases, which affect cellular processes by the enzymatic transfer of the terminal phosphate group of ATP to the hydroxyl of the serine, threonine or tyrosine side chain of a protein, has been established as one of the most promising therapeutic strategies to address diseases such as cancer. Any mutations of protein kinase molecules lead to the autonomous and uncontrolled behavior of cancer cells, disrupting the mechanisms that regulate cell division, survival and apoptosis. Inhibition of pathological protein kinases by small molecular weight molecules, which compete for the ATP binding site in the active site of the kinase, has been shown by studies to contribute significantly to the treatment and treatment of neoplasms. Precisely for this reason, there is great interest in the scientific community for the development and production of new protein kinase inhibitors, which will act selectively, inhibiting the activity of only the pathological protein kinase.Lenvatinib, a drug approved by the FDA in May 2016, is a reversible selective inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2) and is given to patients for the treatment of differentiated thyroid cancer after they have not responded with radioactive iodine. In addition, the FDA approved Lenvatinib for the treatment of advanced renal cell carcinoma, as it has a better inhibitory effect than the existing drugs Sorafenib and Sunitinib.In the present work, during the preparation of the PhD thesis, the synthesis of analogues/derivatives of Lenvatinib was achieved by replacing the urea structure with that of the amide bond as well as the cyclopropane with the structures of furan, thiophene, thiazole and a natural amino acid, L-proline. These targeted modifications are the result of molecular modeling, so that the new potential inhibitors act more effectively against the vascular endothelial growth factor receptor 2 (VEGFR2), with the aim of selectively inhibiting it. In addition, during the PhD thesis, an attempt was made to develop an optimized overall course of synthesis of the pharmaceutical formulation Lenvatinib. Finally, the Lenvatinib analogs synthesized in the laboratory were subjected to a first biological screening against the MC-7 tumor line.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Alagiannis, Michalis
- Αλαγιάννης, Μιχάλης
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52829